The expiration of semaglutide patents is triggering an influx of low-cost generics, compelling major players to reassess pricing strategies as investor sentiment teeters amid anticipated selling pressure. While FDA approvals and strong revenue growth from obesity therapies appear promising, the looming price-level compression and safety concerns surrounding new compounds raise doubts about sustained bullish momentum.
“With the patent expiry of Semaglutide, the key ingredient behind blockbuster drugs like Ozempic and Wegovy, prices are set to crash as dozens of local pharma companies launch generics.”
“India’s anti-obesity and diabetes drug market is heading for a sharp price reset, with generic semaglutide makers preparing to launch products at prices that could significantly undercut Novo Nordisk’s branded portfolio.”
“India’s anti-obesity and diabetes drug market is heading for a sharp price reset, with generic semaglutide makers preparing to launch products at prices that could significantly undercut Novo Nordisk’s branded portfolio.”
“Ozempic and Wegovy made weight loss a global talking point, now their key ingredient is set to go generic in many countries, including India.”
“As of today, the patent on semaglutide, the key ingredient behind Novo Nordisk’s hugely popular drugs Wegovy and Ozempic, is no longer protected in India. That single change could unleash a wave of low-cost alternatives.”
“Indian pharma companies are now free to manufacture their own versions, and if past trends are anything to go by, prices could drop sharply - making these drugs accessible to far more people.”
“Ozempic is set to become as cheap as $14. That single change could unleash a wave of low-cost alternatives. Indian pharma companies are now free to manufacture their own versions, and if past trends are anything to go by, prices could drop sharply.”
“Ozempic copies will cost as low as $14 in India as the era of generic GLP-1 begins”
“India has just entered its Ozempic era. With the patent expiry of Semaglutide, the key ingredient behind blockbuster drugs like Ozempic and Wegovy, prices are set to crash as dozens of local pharma companies launch generics.”
“With the patent expiry of Semaglutide, the key ingredient behind blockbuster drugs like Ozempic and Wegovy, prices are set to crash as dozens of local pharma companies launch generics.”
“#FPCreatives: Ozempic and Wegovy made weight loss a global talking point”
“now their key ingredient is set to go generic in many countries, including India.”
.svg&width=160)